Combined, Sequential Intravenous and Intra-Arterial Chemotherapy (Bridge Chemotherapy) for Young Infants with Retinoblastoma
Open Access
- 18 September 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (9) , e44322
Abstract
Intra-arterial (IA) chemotherapy has more risks of procedural complications in neonates and young infants. For these reasons, we have developed a strategy of bridge intravenous single agent chemotherapy to postpone IA chemotherapy in these children Neonates and young infants with retinoblastoma who required chemotherapy were treated with systemic carboplatin chemotherapy (18.7 mg/kg IV every 3–4 weeks) until they reached the age of 3 months and a weight of 6 Kg. If necessary, IA chemotherapy was subsequently performed at 4 weeks intervals. Efficacy was judged by tumor regression on ophthalmological examination. Retinal toxicity was judged by electroretinography. Eleven children (19 eyes) were treated. All patients are alive and no patient has developed metastatic disease or second malignancies (mean follow-up 27 months, range 9–46 months). Intravenous carboplatin (median 2 cycles, range 1–5) combined with cryotherapy and laser was given to all children. This was effective for five eyes, which did not require IA chemotherapy. IA chemotherapy was administered to 14 eyes (median 3.5 cycles per eye, range 1 to 6). No radiation therapy was required. The Kaplan Meier estimate of ocular radiation-free survival was 94.7% at one year (95% confidence interval 68.1–99.2%). One eye was enucleated due to tumor progression. ERG showed no deterioration of retinal function. Bridge IV-IA chemotherapy was feasible and safe, and is a promising strategy to treat retinoblastoma in neonates and young infants.Keywords
This publication has 26 references indexed in Scilit:
- Efficacy and Complications of Super-selective Intra-ophthalmic Artery Melphalan for the Treatment of Refractory RetinoblastomaOphthalmology, 2012
- Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: preliminary results from 140 treatmentsActa Ophthalmologica, 2012
- OCCURRENCE OF SECTORAL CHOROIDAL OCCLUSIVE VASCULOPATHY AND RETINAL ARTERIOLAR EMBOLIZATION AFTER SUPERSELECTIVE OPHTHALMIC ARTERY CHEMOTHERAPY FOR ADVANCED INTRAOCULAR RETINOBLASTOMARetina, 2011
- Histopathologic Findings of Eyes Enucleated After Treatment with Chemosurgery for RetinoblastomaThe Open Ophthalmology Journal, 2011
- Spontaneously resolving periocular erythema and ciliary madarosis following intra-arterial chemotherapy for retinoblastomaMiddle East African Journal of Ophthalmology, 2010
- Cancer mortality in long-term survivors of retinoblastomaEuropean Journal of Cancer, 2009
- Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastomaDocumenta Ophthalmologica, 2009
- Treatment of Retinoblastoma Patients With Chemoreduction Plus Local Therapy: Experience of the AC Camargo Hospital, BrazilJournal of Pediatric Hematology/Oncology, 2006
- The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastomaInternational Journal of Clinical Oncology, 2004
- Retinoblastoma in the first year of lifeOphthalmic Paediatrics and Genetics, 1992